首页 | 官方网站   微博 | 高级检索  
     

延胡索乙素固体脂质纳米粒缓释片制备及工艺优化
引用本文:谢燕,崔晓鸽,张智强. 延胡索乙素固体脂质纳米粒缓释片制备及工艺优化[J]. 中国医院药学杂志, 2019, 39(21): 2134-2140. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.21.02
作者姓名:谢燕  崔晓鸽  张智强
作者单位:1. 郑州澍青医学高等专科学校药学系, 河南 郑州 450064;2. 天津药物研究院药业有限责任公司, 天津 300301
基金项目:"十三五"国家科技重大专项(编号:2017ZX09301062);天津市科技支撑重点项目(编号:17YFZCSY01170)
摘    要:目的:制备延胡索乙素固体脂质纳米粒缓释片,并研究延胡索乙素固体脂质纳米粒缓释片的释药模型和释药机理。方法:乳化-溶剂挥发法制备延胡索乙素固体脂质纳米粒,以乳糖作为冻干剂,羟丙基甲基纤维素(HPMC)为缓释材料进一步制备缓释片。在单因素考察的基础上,设计正交试验优化延胡索乙素固体脂质纳米粒缓释片处方,并对缓释片体外释药模型和释药机理进行探讨。结果:延胡索乙素固体脂质纳米粒缓释片最佳处方为缓释材料HPMC K4M和HPMC K15M比例为1:1,用量为40 mg,PEG 4000的用量为20 mg,硬脂酸镁用量为片芯质量的0.5%。延胡索乙素固体脂质纳米粒缓释片最佳处方的体外释放行为符合Higuchi释药模型,释药方程为:Mt/M=0.286 8 t1/2-0.073 8(r=0.990 8),12 h内累积释放度为93.56%,缓释片释药机理为扩散和溶蚀共存。结论:制备的延胡索乙素固体脂质纳米粒缓释片,工艺重复性较好,其释药行为符合Higuchi释药模型。

关 键 词:延胡索乙素  固体脂质纳米粒  正交设计  骨架缓释片  释药机制  
收稿时间:2019-05-11

Hydrogel matrix sustained-release tablets of tetrahydropalmatine-solid lipid nanoparticles: Preparation and prescription optimization
XIE Yan,CUI Xiao-ge,ZHANG Zhi-qiang. Hydrogel matrix sustained-release tablets of tetrahydropalmatine-solid lipid nanoparticles: Preparation and prescription optimization[J]. Chinese Journal of Hospital Pharmacy, 2019, 39(21): 2134-2140. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.21.02
Authors:XIE Yan  CUI Xiao-ge  ZHANG Zhi-qiang
Affiliation:1. Department of Pharmacy, Zhengzhou Shuqing Medical College, Henan Zhengzhou 450064, China;2. Tianjin Institute of Pharmaceutical Research Pharmaceutical Co., Ltd, Tianjin 300301, China
Abstract:OBJECTIVE To prepare tetrahydropalmatine solid lipid nanoparticle sustained-release tablets and study the release model and mechanism of tetrahydropalmatine solid lipid nanoparticle sustained-release tablets.METHODS Solid lipid nanoparticles of tetrahydropalmatine were prepared by emulsification-solvent evaporation method. Lactose was used as lyophilizer and hydroxypropyl methylcellulose(HPMC) was used as sustained-release material to prepare sustained-release tablets.On the basis of single factor investigation, orthogonal test was designed to optimize the formulation of tetrahydropalmatine solid lipid nanoparticles sustained-release tablets, and the in vitro release model and drug release mechanism of sustained-release tablets were discussed. RESULTS The optimum formula of Yanhusuo B solid lipid nanoparticle sustained-release tablets was that the ratio of HPMC K4M to HPMC K15M was 1:1, the dosage was 40 mg, the dosage of PEG 4000 was 20 mg, and the dosage of magnesium stearate was 0.5% of the tablet core.The in vitro release behavior of the optimal formulation of Yanhusuo B solid lipid nanoparticle extended-release tablets conformed to the Higuchi release model, and the release equation was Mt/M=0.286 8t1/2-0.073 8(r=0.990 8). Accumulative release of the prepared hydrogel matrix sustained-release tablets was 93.56% within 12 h. The drug release from the hydrogel matrix sustained-release tablets was controlled by diffusion and degradation of the matrix. CONCLUSION The reproducibility of optimized formulations of tetrahydropalmatine solid lipid nanoparticles sustained-release tablets was favorable, and the drug release behavior conforms to the character of Higuchi model.
Keywords:tetrahydropalmatine  solid lipid nanoparticles  orthogonal test  hydrogel matrix sustained-release tablet  release mechanism  
点击此处可从《中国医院药学杂志》浏览原始摘要信息
点击此处可从《中国医院药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号